|Bid||119.81 x 2200|
|Ask||119.90 x 800|
|Day's Range||119.02 - 122.00|
|52 Week Range||86.16 - 128.54|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||47.65|
|Earnings Date||Apr 20, 2021|
|Forward Dividend & Yield||1.80 (1.45%)|
|Ex-Dividend Date||Apr 14, 2021|
|1y Target Est||134.95|
Abbott Laboratories (NYSE: ABT) entered 2020 as a strong and growing business. For the quarter, Abbott Labs reported revenue of $10.5 billion, a 35% year-over-year jump. In the prior-year period, Abbott posted GAAP earnings of $564 million, or $0.31 per share.
Abbott Laboratories posted a "rare, off-color" first-quarter earnings report, an analyst said Tuesday as total and Covid-related sales came in light. In response, ABT stock fell.
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.